Tumor refractoriness to endostatin anti-angiogenesis is associated with the recruitment of CD11b+Gr1+ myeloid cells and inflammatory cytokines

Tumori

Volumn 99, Issue 6, 2013, Pages 723-733

  Zhang, Hui ^a   Wang, Zi ^a   Peng, Qian ^a   Liu, Yan Yang ^a   Zhang, Wei ^a   Wu, Lu ^a   Wang, Xia ^a   Luo, Feng ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

CD11b+Gr1+ myeloid cells; Endostatin; Inflammatory cytokines; Tumor refractoriness

Indexed keywords

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIGENS, CD11B; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CYTOKINES; ENDOSTATINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HETEROGRAFTS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MYELOID CELLS; NEOPLASMS, EXPERIMENTAL; NF-KAPPA B; RANDOM ALLOCATION; UP-REGULATION; VERSICANS;

EID: 84894289515     PISSN: 03008916     EISSN: 20382529     Source Type: Journal    
DOI: 10.1700/1390.15462     Document Type: Article

References (37)

1. Folkman J: Tumor angiogenesis: therapeutic implications. N Engl J Med, 285: 1182-1186, 1971.
2. Damia G, D'Incalci M: Contemporary pre-clinical development of anticancer agents-what are the optimal preclinical models? Eur J Cancer, 45: 2768-2781, 2009.
3. Pàez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Viñals F, Inoue M, Bergers G, Hanahan D, Casanovas O: Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell, 15: 220-231, 2009
4. Keunen O, Johansson M, Oudin A, Sanzey M, Rahim SA, Fack F, Thorsen F, Taxt T, Bartos M, Jirik R, Miletic H, Wang J, Stieber D, Stuhr L, Moen I, Rygh CB, Bjerkvig R, Niclou SP: Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc Natl Acad Sci USA, 108: 3749-3754, 2011.
5. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS: Accelerated metastasis after shortterm treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell, 15: 232-239, 2009.
6. Shojaei F: Anti-angiogenesis therapy in cancer: current challenges and future perspectives. Cancer Lett, 320: 130-137, 2012.
7. Gerber HP, Olazoglu E, Grewal IS: Targeting inflammatory cells to improve anti-VEGF therapies in oncology. Recent Results Cancer Res, 180: 185-200, 2010.
8. Shojaei F, Zhong C, Wu X, Yu L, Ferrara N: Role of myeloid cells in tumor angiogenesis and growth. Trends Cell Biol, 18: 372-378, 2008.
9. Gabrilovich DI, Nagaraj S: Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol, 9: 162-174, 2009.
10. Shojaei F, Wu X, Malik AK, Zhong C, Baldwin ME, Schanz S, Fuh G, Gerber HP, Ferrara N: Tumor refractoriness to anti- VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat Biotechnol, 25: 911-920, 2007. (Pubitemid 47236916)
11. Finke J, Ko J, Rini B, Rayman P, Ireland J, Cohen P: MDSC as a mechanism of tumor escape from sunitinib-mediated antiangiogenic therapy. Int Immunopharmacol, 11: 856-861, 2011.
12. Carbone C, Moccia T, Zhu C, Paradiso G, Budillon A, Chiao PJ, Abbruzzese JL, Melisi D: Anti-VEGF treatment-resistant pancreatic cancers secrete proinflammatory factors that contribute to malignant progression by inducing an EMT cell phenotype. Clin Cancer Res, 17: 5822-5832, 2011.
13. Shojaei F, Wu X, Qu X, Kowanetz M, Yu L, Tan M, Meng YG, Ferrara N: G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models. Proc Natl Acad Sci USA, 106: 6742-6747, 2009.
14. Ling Y, Yang Y, Lu N, You QD, Wang S, Gao Y, Chen Y, Guo QL: Endostar, a novel recombinant human endostatin, exerts antiangiogenic effect via blocking VEGF-induced tyrosine phosphorylation of KDR/Flk-1 of endothelial cells. Biochem Biophys Res Commun, 361: 79-84, 2007. (Pubitemid 47102270)
15. Folkman J: Antiangiogenesis in cancer therapy - endostatin and its mechanisms of action. Exp Cell Res, 312: 594-607, 2006.
16. Wang HL, Ning T, Li M, Lu ZJ, Yan X, Peng Q, Lei N, Zhang H, Luo F: Effect of endostatin on preventing postoperative progression of distant metastasis in a murine lung cancer model. Tumori, 97: 787-793, 2011.
17. Huang G, Chen L: Discrepancies between antiangiogenic and antitumor effects of recombinant human endostatin. Cancer Biother Radiopharm, 24: 589-596, 2009.
18. Ning T, Jiang M, Peng Q, Yan X, Lu ZJ, Peng YL, Wang HL, Lei N, Zhang H, Lin HJ, Li M and Luo F: Low-dose endostatin normalizes the structure and function of tumor vasculature and improves the delivery and anti-tumor efficacy of cytotoxic drugs in a lung cancer xenograft murine model. Thoracic Cancer, 3: 229-238. 2012.
19. Li XQ, Shang BY, Wang DC, Zhang SH, Wu SY, Zhen YS: Endostar, a modified recombinant human endostatin, exhibits synergistic effects with dexamethasone on angiogenesis and hepatoma growth. Cancer Lett, 301: 212-220, 2011.
20. Ljung BM, Mayall B, Lottich C, Boyer C, Sylvester SS, Leight GS, Siegler HF, Smith HS: Cell dissociation techniques in human breast cancer - variations in tumor cell viability and DNA ploidy. Breast Cancer Res Treat, 13: 153-159, 1989. (Pubitemid 19120107)
21. Ko JS, Zea AH, Rini BI, Ireland JL, Elson P, Cohen P, Golshayan A, Rayman PA, Wood L, Garcia J, Dreicer R, Bukowski R, Finke JH: Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res, 15: 2148-2157. 2009.
22. Kim EJ, Hong JE, Eom SJ, Lee JY, Park JH: Oral administration of benzyl-isothiocyanate inhibits solid tumor growth and lung metastasis of 4T1 murine mammary carcinoma cells in BALB/c mice. Breast Cancer Res Treat, 130: 61-71, 2011.
23. Kim EJ, Choi MR, Park H, Kim M, Hong JE, Lee JY, Chun HS, Lee KW, Yoon Park JH: Dietary fat increases solid tumor growth and metastasis of 4T1 murine mammary carcinoma cells and mortality in obesity-resistant BALB/c mice. Breast Cancer Res, 13: R78, 2011.
24. Ostrand-Rosenberg S, Sinha P: Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol, 182: 4499-4506, 2009.
25. Ben-Neriah Y, Karin M: Inflammation meets cancer, with NF-κB as the matchmaker. Nat Immunol, 12: 715-723, 2011.
26. Kim S, Takahashi H, Lin WW, Descargues P, Grivennikov S, Kim Y, Luo JL, Karin M: Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature, 457: 102-106, 2009.
27. Meyer C, Sevko A, Ramacher M, Bazhin AV, Falk CS, Osen W, Borrello I, Kato M, Schadendorf D, Baniyash M, Umansky V: Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model. Proc Natl Acad Sci USA, 108: 17111-17116, 2011.
28. Yang L, DeBusk LM, Fukuda K, Fingleton B, Green-Jarvis B, Shyr Y, Matrisian LM, Carbone DP, Lin PC: Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumorbearing host directly promotes tumor angiogenesis. Cancer Cell, 6: 409-421, 2004. (Pubitemid 39361441)
29. Wight TN: Versican: a versatile extracellular matrix proteoglycan in cell biology. Curr Opin Cell Biol, 14: 617-623, 2002.
30. Gao D, Joshi N, Choi H, Ryu S, Hahn M, Catena R, Sadik H, Argani P, Wagner P, Vahdat LT, Port JL, Stiles B, Sukumar S, Altorki NK, Rafii S, Mittal V: Myeloid progenitor cells in the premetastatic lung promote metastases by inducing mesenchymal to epithelial transition. Cancer Res, 72: 1384-1394, 2012.
31. Franco M, Man S, Chen L, Emmenegger U, Shaked Y, Cheung AM, Brown AS, Hicklin DJ, Foster FS, Kerbel RS: Targeted anti-vascular endothelial growth factor receptor-2 therapy leads to short-term and long-term impairment of vascular function and increase in tumor hypoxia. Cancer Res, 66: 3639-3648, 2006.
32. Rapisarda A, Melillo G: Role of the hypoxic tumor microenvironment in the resistance to anti-angiogenic therapies. Drug Resist Update, 12: 74-80, 2009.
33. Asplund A, Stillemark-Billton P, Larsson E, Rydberg EK, Moses J, Hult en LM, Fagerberg B, Camejo G, Bondjers G: Hypoxic regulation of secreted proteoglycans in macrophages. Glycobiology, 20: 33-40, 2010.
34. Cramer T, Yamanishi Y, Pawlinski R, Mackman N: HIF-1α is essential for myeloid cell-mediated inflammation. Cell, 112: 645-657, 2003. (Pubitemid 36331777)
35. Jain RK: Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science, 307: 58-62, 2005.
36. Kuroiwa M, Takeuchi T, Lee JH, Yoshizawa J, Hirato J, Kaneko S, Choi SH, Suzuki N, Ikeda H, Tsuchida Y: Continuous versus intermittent administration of human endostatin in xenografted human neuroblastoma. J Pediatr Surg, 38: 1499-1505, 2003. (Pubitemid 37238794)
37. Reck M, Pawel JV, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, Leighl N, Mezger J, Archer V, Moore N, Manegold C: Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAIL. J Clin Oncol, 27: 1227-1234, 2009.